Advancing Concept to Clinic Vaccine Stewardship
Rationally Engineered Immunogens
Structural Vaccinology based Systems and Tools for Immunogenicity Enhancement
Citranvi Biosciences is a pre-clinical stage company engaged in the design and development of novel systems and tools for immunogenicity enhancement, applicable to Vaccines Research and Development.
We are developing innovative, proprietary vaccine technology platforms and products, using comprehensive Structure-based Vaccine Design, broadly applicable to a variety of preventable disease targets, where there is an unmet medical need, across the globe.
Citranvi is also partnering with Henry M. Jackson Foundation for Advancement of Military Medicine to develop Vaccines to target Herpesviruses such as human Cytomegalovirus (hCMV) and Epstein-Barr Virus (EBV). Infection with hCMV or EBV can lead to significant health complications and their smoldering latency can cause viral transmission and reactivation flare-ups. The latent stage is frequently interrupted by reactivation episodes and can lead to severe disease outcomes. Congenital CMV has a significant maternal-to-infant infection rate and is the most common infectious cause of brain damage and sensorineural hearing loss (SNHL) in infants. The fetuses of hCMV seronegative women acutely infected in pregnancy are at a particularly high risk for infection, as up to 40% of primary maternal infections result in congenital hCMV transmission. CMV infection also remains one of the most common complications affecting patient survival among solid organ transplant (SOT) and hematopoietic stem cell transplantation (HSCT) patients. Nearly 30%-40% of adolescents who contract EBV will develop infectious mononucleosis (IM), which can lead to serious complications such as liver failure, splenic rupture and hematologic disorders. EBV is also linked with an increased risk for autoimmune disorders and with nearly 140,000 cancers deaths annually. EBV is sharply associated with sequelae such as Hodgkin's lymphoma and multiple sclerosis. Infection of children with EBV in many parts of the world, such as Africa and Asia, is also associated with Burkitt's lymphoma, gastric adenocarcinoma and nasopharyngeal carcinoma. Young children and adults worldwide who undergo SOT or HSCT have a significant risk for development of post-transplant lymphoproliferative disorders (PTLD) due to EBV infection. Currently, there are no commercially licensed hCMV or EBV vaccines. Therefore, there is a significant unmet medical need to address the infections and sequelae attributed to hCMV and EBV.
Citranvi is also partnering with Henry M. Jackson Foundation for Advancement of Military Medicine to develop Vaccines to target Herpesviruses such as human Cytomegalovirus (hCMV) and Epstein-Barr Virus (EBV). Infection with hCMV or EBV can lead to significant health complications and their smoldering latency can cause viral transmission and reactivation flare-ups. The latent stage is frequently interrupted by reactivation episodes and can lead to severe disease outcomes. Congenital CMV has a significant maternal-to-infant infection rate and is the most common infectious cause of brain damage and sensorineural hearing loss (SNHL) in infants. The fetuses of hCMV seronegative women acutely infected in pregnancy are at a particularly high risk for infection, as up to 40% of primary maternal infections result in congenital hCMV transmission. CMV infection also remains one of the most common complications affecting patient survival among solid organ transplant (SOT) and hematopoietic stem cell transplantation (HSCT) patients. Nearly 30%-40% of adolescents who contract EBV will develop infectious mononucleosis (IM), which can lead to serious complications such as liver failure, splenic rupture and hematologic disorders. EBV is also linked with an increased risk for autoimmune disorders and with nearly 140,000 cancers deaths annually. EBV is sharply associated with sequelae such as Hodgkin's lymphoma and multiple sclerosis. Infection of children with EBV in many parts of the world, such as Africa and Asia, is also associated with Burkitt's lymphoma, gastric adenocarcinoma and nasopharyngeal carcinoma. Young children and adults worldwide who undergo SOT or HSCT have a significant risk for development of post-transplant lymphoproliferative disorders (PTLD) due to EBV infection. Currently, there are no commercially licensed hCMV or EBV vaccines. Therefore, there is a significant unmet medical need to address the infections and sequelae attributed to hCMV and EBV.
